Therapy Areas: Vaccines
COVAXX signs advanced purchase commitments worth USD2.8bn for COVID-19 vaccine
26 November 2020 -

Vaccine development company COVAXX, a subsidiary of United Biomedical Inc, said on Wednesday that it has agreed advanced purchase commitments for more than 140 million doses of its UB-612 vaccine against COVID-19.

These public and private commitments, valued at over USD2.8bn, will see the vaccine delivered to multiple countries, including Brazil, Ecuador and Peru.

The announcement follows the start of human trials of the multitope, synthetic peptide-based vaccine candidate in Taiwan and an agreement with Diagnosticos da America SA (Dasa SA), a clinical diagnostic company in Brazil, to conduct Phase 2/3 clinical trials and distribute vaccines within Brazil.

COVAXX also has an agreement with the University of Nebraska Medical Center (UNMC), home of the National Pandemic Center, to conduct trials in the United States.